Clinical Trials Logo

Pneumonia clinical trials

View clinical trials related to Pneumonia.

Filter by:

NCT ID: NCT06282835 Recruiting - Clinical trials for Pneumonia, Bacterial

Eravacycline Combination Therapy for MRAB

Start date: January 26, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about the eravacycline combination therapy in multidrug-resistant acinetobacter gaumannii pneumonia. The main question is to evaluate the the effectiveness and safety. Participants will be given Eravacycline and Polymyxin,or other antibiotcs that the Investigator considered suitable. During the clinical trial, participants will be monitored for blood drug concentrations and drug concentrations in the ELF (Epithelial Lining Fluid。Clinical efficacy rate and microbiological clearance rate will be assessed at the same time

NCT ID: NCT06279910 Recruiting - Clinical trials for SARS-CoV 2 Pneumonia

Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

COVIDIOL
Start date: February 21, 2024
Phase:
Study type: Observational

Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Gerencia de Atención Integrada (GAI) de Albacete". "Complejo Hospitalario Universitario de Albacete". Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy.

NCT ID: NCT06279624 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Effectiveness of the PCV13 in Older Thai Adults

Start date: February 2024
Phase:
Study type: Observational

This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024. The investigators define a CASE as a person aged ≥60 years due to pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. While a CONTROL is defined as a person aged ≥60 years due to non-pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. The goal of this observational study is to evaluate the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in pneumococcal CAP in Thai adults aged ≥ 60 years with or without any medical conditions. The main questions it aims to answer is: • What are the effectiveness of PCV13 for preventing all typed, vaccine typed, or non-vaccine typed of pneumococcal CAP among Thai older adults? The investigators retrospectively collect cases and control who are diagnosed with CAP accordingly from January 2012 through October 2023. The investigators define case and control the same as prospective method, but all data were retrieved from archive database. -The investigators select a 1:2 matched control with criteria as follows; 10-year-interval of age, ward (the same patient care such as out or in-patient, or admitted in the same level ward). Participants will be - collated from hospital database regarding their CAP illnesses by pneumococcal and non-pneumococcal pneumonia condition. - explored their vaccine status by either vaccine book checking or hospital database. Researcher will compare the effectiveness of PCV13 to prevent all typed, vaccine typed and non-vaccine typed pneumococcal pneumonia.

NCT ID: NCT06274931 Recruiting - Pneumonia Clinical Trials

Analysis of the Pulmonary Microbiome

Start date: February 1, 2024
Phase:
Study type: Observational

The purpose of the protocol is to study the pulmonary microbiome in patients who develop pneumonia.

NCT ID: NCT06272994 Enrolling by invitation - Clinical trials for Community-acquired Pneumonia

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin

STOP-Vanc
Start date: April 3, 2024
Phase: N/A
Study type: Interventional

This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for critically ill adults with community-acquired pneumonia when compared with usual care.

NCT ID: NCT06269900 Not yet recruiting - Clinical trials for Hospital Acquired Pneumonia

Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype

HAP-DEX
Start date: February 15, 2024
Phase: Phase 3
Study type: Interventional

Determine the efficacy of dexamethasone plus standard of care (SOC) as compared to placebo plus SOC for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype; It's an international phase III, double-blind, placebo-controlled, randomized trial.

NCT ID: NCT06265389 Not yet recruiting - Clinical trials for Pentoxifylline as an Adjunct Therapy in the Treatment of Pneumonia

Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug

Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

Pentoxifylline is a xanthine-derived, commercially produced drug approved for the management of intermittent claudication in patients suffering from a chronic occlusive arterial disease of the limbs. Pentoxifylline has been documented to display anti-inflammatory and immunomodulatory effects, as well as some antithrombotic and antiviral effects. This drug has also been shown to reduce lung fibrosis in patients with COVID-19, as well as to prevent thromboembolic events. This work aims to assess the benefit of oral Pentoxifyllin supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community-acquired pneumonia

NCT ID: NCT06263881 Recruiting - Pneumonia Clinical Trials

Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia

Start date: December 1, 2023
Phase: Phase 3
Study type: Interventional

Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.

NCT ID: NCT06261827 Recruiting - Clinical trials for Nosocomial Pneumonia

High-dose Inhaled NO Therapy for the pREvenvention of NP After Cardiac Surgery Under CPB

Start date: February 20, 2024
Phase: N/A
Study type: Interventional

The primary aim of this single-center, prospective, randomized, controlled, study is to test the hypothesis that inhalation of NO 200 ppm prevents the development of nosocomial pneumonia in patients at risk after cardiac surgery under CPB. The study is interventional. Examination and treatment of patients is carried out in accordance with the approved standards of medical care for the relevant diseases. During the study, no experimental or unregistered (not approved for use) medical or diagnostic procedures in the territory of the Russian Federation will be carried out. The study includes patients admitted to the Cardiac Surgery Department of Cardiology Research Institute of Tomsk National Research Medical Center for elective surgery with CPB.

NCT ID: NCT06259110 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Community-Acquired Pneumonia Diagnosis Through Integrating Novel Microbiological Techniques.

Start date: February 25, 2024
Phase:
Study type: Observational

To evaluate novel microbiological techniques for enhanced Pathogen Identification, assess the speed and efficiency of the integrated approach in providing timely diagnostic results, aiming to reduce the turnaround time for CAP diagnosis and subsequently improve patient outcomes and evaluate the clinical impact of enhanced precision in CAP diagnosis on treatment decisions, including the potential for targeted and more effective antimicrobial therapy based on accurate pathogen identification.